Skip to main content

An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid

Buy Article:

$43.00 plus tax (Refund Policy)

Twenty-five patients with mucous membrane pemphigoid (MMP), whose oral lesions were unresponsive to topical steroid treatment, were treated with 1 g daily of sulphamethoxypyridazine (SMXP), a long-acting sulphonamide antibiotic, in an open prospective clinical trial. Lesion severity was assessed objectively in a semiquantitative fashion before treatment and after 14 weeks of treatment. The patient’s subjective assessment of the associated pain or discomfort, using a visual analogue scale, was also recorded at these times. Three patients (12%) were withdrawn from the study owing to side-effects or complications, one due to an allergic reaction, the other two because of significant haemolysis. For the remainder there was a significant improvement in the mean objective clinical scores for desquamative gingivitis, other oral lesions, conjunctival inflammation, nasal, vulvovaginal and skin involvement, after 14 weeks treatment with SMXP (all P < 0·001, except skin P < 0·01). Only conjunctival scarring showed no improvement. In addition, there was a significant improvement (P < 0·001) in the pain scores for the mouth, eyes, nose, vulvovaginal region and skin. The results indicate that with appropriate monitoring SMXP is an effective treatment for MMP and compares favourably with other systemic agents used in the management of this condition.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: clinical trial; mucous membrane pemphigoid; sulphamethoxypyridazine

Document Type: Research Article

Affiliations: 1: The Department of Oral Medicine, St Bartholomew’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, U.K. 2: The Unit of Oral Medicine, The University Dental Hospital of Manchester, Higher Cambridge Street, Manchester M15 6FH, U.K.

Publication date: 2000-07-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more